AcuityBio has developed a unique drug-device implant called ABC103 which prevents post-surgical lung cancer recurrence. Pre-IND meeting with FDA have been extremely positive, confirming a clear path for regulatory approval of ABC103 through 505(b)(2)-Orphan Drug pathway. AcuityBio is led by an experienced team of industry veterans and Advisors and is syndicating $3M Series A to support our clinical program and on to a $200-$400M exit by 2020.